Selected article for: "multiple sclerosis and tumor necrosis factor alpha"
Author: Lima Martínez, Marcos M.; Contreras, Miguel A.; Marín, Waleskha; D’Marco, Luis
Title: Statins in COVID-19: Is there any foundation?
  • Cord-id: x4lu3och
  • Document date: 2020_11_7
    • ID: x4lu3och
    Snippet: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19). Acute respiratory distress syndrome is the main cause of death from COVID-19 and occurs due to an exaggerated inflammatory response that causes the release of pro-inflammatory cytokines such as interleukins and tumor necrosis factor-alpha (TNF-α). Statins are lipid lowering drugs with pleiotropic effects. They have shown benefit in the management of inflammatory and autoimmun
    Document: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causal agent of coronavirus disease 2019 (COVID-19). Acute respiratory distress syndrome is the main cause of death from COVID-19 and occurs due to an exaggerated inflammatory response that causes the release of pro-inflammatory cytokines such as interleukins and tumor necrosis factor-alpha (TNF-α). Statins are lipid lowering drugs with pleiotropic effects. They have shown benefit in the management of inflammatory and autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis and multiple sclerosis. Furthermore, due to their immunomodulatory properties, they have been used in the treatment of various infectious diseases such as community-acquired pneumonia and influenza. In this review we analyze the pathophysiological foundations that support the use of statins as an adjunctive treatment in patients with COVID-19.

    Search related documents:
    Co phrase search for related documents
    • abnormal liver test and liver test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • ace enzyme and activation inhibit: 1
    • ace enzyme and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • ace enzyme and acute mers cov respiratory syndrome: 1
    • ace enzyme and adjuvant treatment: 1
    • ace enzyme and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
    • ace enzyme and lung damage: 1, 2, 3, 4, 5
    • ace enzyme and lung level: 1, 2, 3
    • activation inhibit and acute ards respiratory distress syndrome: 1, 2
    • activation inhibit and adjuvant treatment: 1
    • activation inhibit and liver disease: 1
    • activation inhibit and lung damage: 1, 2
    • acute ards respiratory distress syndrome and adjuvant treatment: 1, 2, 3, 4
    • acute ards respiratory distress syndrome and liver disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute ards respiratory distress syndrome and liver profile: 1
    • acute ards respiratory distress syndrome and liver test: 1, 2, 3
    • acute ards respiratory distress syndrome and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and lung level: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute mers cov respiratory syndrome and lung damage: 1, 2